Phaseline

Targets › TYMP

TYMP (Thymidine phosphorylase): drug programs, companies and trials

9 programs from 9 companies in 11 trials: 6 Phase 2, 5 Phase 1; Oncology; next expected readout Nov 2026.

May have a role in maintaining the integrity of the blood vessels. Has growth promoting activity on endothelial cells, angiogenic activity in vivo and chemotactic activity on endothelial cells in vitro..; FUNCTION: Catalyzes the reversible phosphorolysis of thymidine. (UniProt, P19971)

Open in Phaseline: the race on TYMP, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Qilu Hospital of Shandong UniversityTipiracil
Thymidine phosphorylase inhibitor
TYMPPhase 2Metastatic Colorectal CancerDec 2026
Ruijin HospitalTrifluridine/tipiracil (TAS-102)
Nucleoside antimetabolite; trifluridine is incorporated into DNA and tipiracil inhibits th
TYMPPhase 2Colo-rectal CancerAug 2027
First Affiliated Hospital of Zhejiang UniversityTipiracil
Thymidine phosphorylase inhibitor
TYMPPhase 2Esophageal Squamous Cell Carcinoma (ESCC)Aug 2027
Sun Yat-sen UniversityTipiracil (TAS-102)
Thymidine phosphorylase inhibitor
TYMPPhase 2Rectal Cancer; Colorectal Cancer MetastaticDec 2027
GERCOR - Multidisciplinary Oncology Cooperative GroupTipiracil
Thymidine phosphorylase inhibitor
TYMPPhase 2Metastatic Colorectal Cancer–
Gruppo Oncologico del Nord-OvestTipiracil
Thymidine phosphorylase inhibitor
TYMPPhase 1Colorectal Cancer MetastaticNov 2026
Yonsei UniversityTipiracil
Thymidine phosphorylase inhibitor
TYMPPhase 1Gastric and Gastroesophageal Junction Adenocarcinoma–
Emory UniversityTipiracil (TAS-102)
Thymidine phosphorylase inhibitor
TYMPPhase 1Colorectal Adenocarcinoma–
National University Hospital, SingaporeTipiracil (TAS-102)
Thymidine phosphorylase inhibitor
TYMPPhase 1Breast Cancer–

Conditions

Colorectal Cancer Metastatic (2) Esophageal Squamous Cell Carcinoma (ESCC) (2) Metastatic Colorectal Cancer (2) Rectal Cancer (1) Colorectal Adenocarcinoma (1) Breast Cancer (1) Gastric and Gastroesophageal Junction Adenocarcinoma (1) Colo-rectal Cancer (1)

Modalities

small molecule (5), antibody (3), mixed (1)

Companies

Sun Yat-sen University (1) First Affiliated Hospital of Zhejiang University (1) Emory University (1) Gruppo Oncologico del Nord-Ovest (1) GERCOR - Multidisciplinary Oncology Cooperative Group (1) Qilu Hospital of Shandong University (1) National University Hospital, Singapore (1) Yonsei University (1) Ruijin Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.